Since the purpose of this pilot clinical study was to verify the feasibility of 99mTc-HP-Ark2 SPECT/CT for the accurate and noninvasive detection of HER2 expression in breast cancer, the investigation of monitoring therapy was not performed in breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.